An inducible Cre mouse line to sparsely target nervous system cells, including Remak Schwann cells by Sapkota, Darshan & Dougherty, Joseph D
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2-20-2020 
An inducible Cre mouse line to sparsely target nervous system 
cells, including Remak Schwann cells 
Darshan Sapkota 
Joseph D Dougherty 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
SHORT REPORT Open Access
An inducible Cre mouse line to sparsely
target nervous system cells, including
Remak Schwann cells
Darshan Sapkota1 and Joseph D. Dougherty1,2*
Abstract
Nerves of the peripheral nervous system contain two classes of Schwann cells: myelinating Schwann cells that
ensheath large caliber axons and generate the myelin sheath, and Remak Schwann cells that surround smaller axons
and do not myelinate. While tools exist for genetic targeting of Schwann cell precursors and myelinating Schwann
cells, such reagents have been challenging to generate specifically for the Remak population, in part because many of
the genes that mark this population in maturity are also robustly expressed in Schwann cell precursors. To circumvent
this challenge, we utilized BAC transgenesis to generate a mouse line expressing a tamoxifen-inducible Cre under the
control of a Remak-expressed gene promoter (Egr1). However, as Egr1 is also an activity dependent gene expressed by
some neurons, we flanked this Cre by flippase (Flpe) recognition sites, and coinjected a BAC expressing Flpe under
control of a pan-neuronal Snap25 promoter to excise the Cre transgene from these neuronal cells. Genotyping and
inheritance demonstrate that the two BACs co-integrated into a single locus, facilitating maintenance of the line.
Anatomical studies following a cross to a reporter line show sparse tamoxifen-dependent recombination in Remak
Schwann cells within the mature sciatic nerve. However, depletion of neuronal Cre activity by Flpe is partial, with some
neurons and astrocytes also showing evidence of Cre reporter activity in the central nervous system. Thus, this mouse
line will be useful in mosaic loss-of-function studies, lineage tracing studies following injury, live cell imaging studies, or
other experiments benefiting from sparse labeling.
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Introduction
Although glia are as abundant as neurons in the verte-
brate nervous system and are essential for neuronal
health and function, they are relatively less studied than
neurons. In the peripheral nervous system (PNS), glial
cells called Schwann cells are most commonly known
for the formation of the myelin sheath, which insulates
and protects axons and ensures that nerve impulses
travel quickly and efficiently [1]. Some Schwann cells,
however, do not form myelin, and these nonmyelinating
Schwann cells are among the least studied cells in the
nervous system. Remak Schwann cells (RSCs), a class of
nonmyelinating Schwann cells, ensheath small, 0.5–
1.5 μm diameter axons, such as C fiber nociceptors in
sciatic nerves and form Remak bundles [2]. It is now ac-
cepted that RSCs provide trophic support to unmyelin-
ated axons [1] and they are also implicated in nerve
regeneration [2] and tumorigenesis [3]. RSCs and myeli-
nating Schwann cells share a common pool of progeni-
tors, which express many known molecular markers of
mature RSCs [4]. This has precluded the generation of
RSC-specific Cre lines and thus hindered progress in un-
derstanding the function of these cells.
When a single cell type-specific cis regulatory element
is not readily available, intersectional BAC (bacterial artifi-
cial chromosome) transgenesis can be used to moderate
the expression of a transgene driven by a promiscuous cis
regulatory element [5–7]. This is achieved by using a sec-
ond transgene that precludes the expression of the first
one in some cells. Most often, this is done by crossing two
transgenic lines together to create a genetic gate. However,
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this is less efficient as only a fraction of the progeny has
both transgenes. We previously demonstrated that mul-
tiple BACs can be integrated into the same locus, yet still
show independent transgene expression [8]. Using a com-
bination of these two strategies, we report a Cre/Flpe bi-
transgenic mouse line that can be used to sparsely target
cells in the nervous system, including RSCs in the PNS
and astrocytes and neurons in the central nervous system
(CNS).
Results
Generation of Egr1-Cre-ERT2; Snap25-Flpe mice
To permit temporally-specific genetic manipulation, we
utilized Cre-ERT2, a tamoxifen-inducible version of Cre
recombinase, and drove its expression with a 92 kb BAC
fragment covering early growth response 1 (Egr1). Egr1,
an immediate early gene, is undetectable in the embryonic
nervous system, and is increasingly induced postnatally,
culminating in a widespread expression in the adult brain
[9, 10]. In the PNS, it is expressed by Schwann cell precur-
sors during development, but confined to non-
myelinating Schwann cells in the adulthood [11]. We rea-
soned that by using a temporally specific Cre, we could
avoid developmental recombination. Further, in order to
restrict Egr1-Cre-ERT2 expression to fewer cell types, we
flanked the Cre-ERT2 cassette with Flippase Recognition
Targets (FRTs), and simultaneously used a 61 kb BAC
covering the neuron-specific synaptosomal-associated
protein 25 kDa (Snap25) [12] to drive Flpe expression. Be-
cause Snap25 is a pan-neuronal gene, we reasoned that
the Cre-ERT2 cassette should be excised by Flpe in neu-
rons during development. Thus, upon tamoxifen injection,
Cre would only be expressed in Egr1-positive/Snap25-
negative cells (e.g. RSCs) (Fig. 1a).
The two BACs were co-injected into the pronuclei of
fertilized mouse eggs, and the resulting progeny were
PCR-genotyped for Cre and Flpe to identify founders
(Fig. 1b). Upon crossing the founders to wildtype
C57BL/6 mice and genotyping multiple F1 mice, we
found that the two transgenes were always co-inherited,
suggesting that they were integrated into a single locus
(data not shown). This feature avoids the need to main-
tain the two alleles independently and hence enhances
the utility of the Egr1-Cre-ERT2; Snap25-Flpe (ECSF)
mouse line.
We next tested if Cre is active in ECSF mice by cross-
ing F1 mice to Ai14 reporter mice. The Ai14 mice have
a LoxP-flanked stop cassette that prevents the expres-
sion of a reporter TdTomato fluorophore unless it is ex-
cised by Cre recombinase [13]. A PCR designed to
detect the excision of this stop cassette indeed showed
that ECSF mice express Cre recombinase at sufficient
levels to mediate recombination upon tamoxifen induc-
tion (Fig. 1c).
Identification of cells expressing Cre in ECSF mice
We first asked if RSCs show Cre activity. The ECSF;Ai14
double heterozygote mice from ECSF X Ai14 cross were
injected with either tamoxifen or vehicle control (sun-
flower oil), and their sciatic nerves were immunostained
for p75 neurotrophin receptor (p75NTR), which marks
Remak bundles [14]. Robust expression of TdTomato
was observed in the nerves from tamoxifen-treated mice,
but not in those from vehicle-treated mice, evidencing a
stringent inducibility of the Cre activity (Fig. 2a). Around
16% of p75NTR-positive cells expressed TdTomato, sug-
gesting that recombination occurred sparsely in RSCs
(Fig. 2b).
We also stained the sciatic nerves for myelin basic pro-
tein (MBP), a marker of myelinating Schwann cells [15].
While TdTomato did not overlap with MBP, it was
present in the center of some of the myelin sheaths, sug-
gesting Cre recombination in some axons (Fig. 3a). Longi-
tudinal sections of the nerves indeed showed a few
TdTomato-expressing axons (Fig. 3b). Comparison of the
numbers of sheaths with and without labelled axons re-
vealed 10.3% of the axons to be targeted after tamoxifen
injection (Fig. 3c). Thus, Cre activity is excluded from
myelinating Schwann cells, confirming the precision of
Egr1-Cre, but present sparsely in peripheral axons, sug-
gesting a partial insufficiency of Snap25-Flpe activity.
Finally, we stained brain sections from tamoxifen- and
vehicle-injected mice for astrocytes (GFAP), neurons
(NEUN), microglia (IBA1) and oligodendrocytes
(CNPase). In Tamoxifen-injected mice, TdTomato clearly
overlapped with sparse astrocytes and neurons, but not
with microglia or oligodendrocytes (Fig. 4a-d). Again,
TdTomato was undiscernible in the brains of vehicle-
injected mice (Fig. 4e). Quantification in the cortex re-
vealed 6.8% of GFAP-positive astrocytes and 11.1% of neu-
rons to be TdTomato positive (Fig. 4f).
Discussion
We introduce the ECSF mouse to genetically target
RSCs and other cell types in the nervous system. We
show that cell targeting in this novel bi-transgenic
mouse is sparse. This suggests a stochastic targeting of
cells or a more uniform targeting of a specific subset of
cells, for example a subset expressing Egr1 abundantly,
or both. In principle, this mouse will be useful in loss-
of-function studies when only a subset of cells needs to
be studied or when possible non cell-autonomous effects
arising from gene deletion need to be avoided. RSCs
have long been thought to transform into repair cells
following nerve injuries [16]. A recent study has pro-
vided direct evidence for this by using a tamoxifen-
inducible Cre mouse in lineage tracing experiments [17].
A single low-dose of tamoxifen in Plp-CreERT2 was
found to target RSCs and a few myelinating Schwann
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cells [17]. We expect the ECSF mouse will also be useful
in similar lineage tracing studies on RSCs. It, however,
may not be ideal for studying gross pathophysiology due
to a loss-of-function mutation.
Although we had expected the Cre activity to be en-
tirely eliminated from neurons, this was not the case,
possibly due to insufficient activity of the Snap25-Flpe
BAC fragment. Yet there are occasions when a line that
can reliably tag sparse neurons would be useful. For ex-
ample, the Brainbow mouse has been an important re-
agent in studying the connectome in the brain [18].
With sparse labeling of neurons in the CNS and axons
in the PNS, the ECSF mouse should be useful for similar
purposes. Therefore, we have donated this mouse to the
Jackson Laboratory (Stock # 033895).
Materials and methods
BAC recombination and pronuclear injection
A FRT-ERT2-Cre-ERT2-FRT cassette and an Egr1 A box
were cloned into a shuttle vector, which was then used
to modify a Egr1 BAC (clone ID: RP23-108C3) using
homologous recombination as described previously [19].
Similarly, a Flpe and a Snap25 A box were cloned into a
shuttle vector, which was used to modify a Snap25 BAC
Fig. 1 Generation of ECSF mice. a Intersectional transgenesis. The two BACs shown were co-injected into mouse eggs to generate double
transgenic mice. In neurons and other cells with active Snap25 promoter, the Flpe recombinase excises the FRT-flanked Cre cassette, thus
inhibiting Cre expression. Remak Schwann cells and other cells with active Egr1 promoter but inactive Snap25 promoter express Cre upon
Tamoxifen treatment. b PCR genotyping of founders. Representative founders with or without the Cre and Flpe transgenes are shown. c Cre
activity in ECSF mice. ECSF mice were crossed to Ai14 mice, which have a LoxP-flanked stop cassette excisable by Cre (upper). The ECSF; Ai14
progeny were injected with tamoxifen or vehicle, and tail preparations were PCRed using primers flanking the Ai14 LoxP sites. Excision of the
stop cassette is evident in mice receiving tamoxifen but not vehicle (lower). ERT2, Estrogen Receptor; FRT, flippase recognition target
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(clone ID: RP23-290A18). BAC modifications were con-
firmed using restriction enzyme digestions followed by
pulsed field gel electrophoresis. For pronuclear injections,
a 92 kb Egr1-FRT-ERT2-Cre-ERT2-FRT BAC fragment
generated from PmeI and PacI double digestion and a 61
kb Snap25-Flpe BAC fragment generated from SbfI and
PmeI double digestion was purified using pulsed field gel
electrophoresis followed by gel extraction (Qiagen
#20021). The pronuclei of fertilized one-cell eggs of
C57BL/6j mice were co-injected with a mixture of equi-
molar amounts of the two fragments by the Department
of Pathology Knockout, Transgenic, and Microinjection
Core, and then implanted into pseudopregnant foster fe-
males. The founders were genotyped using PCR. Trans-
mission was detected in a single founder which was then
crossed to C57BL/6j mice.
Fig. 2 ECSF mice sparsely label Remak Schwann cells. a ECSF; Ai14 mice were injected with tamoxifen or vehicle and the sciatic nerves
immunostained for Remak Schwann cells (p75NTR, green) and nuclei (DAPI, blue). TdTomato is undetectable in vehicle-injected mice (top) and
induced sparsely in Remak Schwann cells by tamoxifen (middle). Boxed area is enlarged to depict targeted (arrowheads) and untargeted (arrows)
Remak Schwann cells (bottom). Note that the perineurium surrounding the nerve is also labeled. Scales bars = 50 μm. b Quantification of cells in
(a) shows 15.96% of Remak Schwann cells are targeted in tamoxifen-injected mice. Three mice; 5 sections/mouse; error bar, standard error
of mean
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Animal care
All procedures involving mice conformed to the Wash-
ington University Institutional Animal Care and Use
Committee. All experimental protocols were approved by
the Animal Studies Committee of Washington University.
Genotyping
Screening of ECSF founders and genotyping of their
progeny were done with PCR using Cre Fwd
(CCGGTCGATGCAACGAGTGATGAGGTTC), Cre
Rev. (GCCAGATTACGTATATCCTGGCAGCG), Flpe
Fwd (CACTGATATTGTAAGTAGTTTGC) and Flpe
Rev. (CTAGTGCGAAGTAGTGATCAGG). The Cre
and Flpe alleles were further confirmed with Sanger
sequencing. Ai14 mice were PCR-genotyped as described
by the Jackson Laboratory for stock number 007914. Cre
recombination activity in ECSF; Ai14 mice was confirmed
with PCR using the Fwd primer GCGGGCCCTAAGAA
GTTCC and Rev. primer TCGCCCTTGCTCACCATG to
detect excision of Stop cassette.
Tamoxifen injection
A 10mg/ml solution of 4-hydroxy-tamoxifen was pre-
pared in a mixture of autoclaved sunflower oil (9 part)
and ethanol (1 part) with end-to-end rotation for 1 h at
room temperature and stored at 4 °C in a light-proof
container. Six-week old mice were injected intraperito-
neally with 2 mg (200 uL) tamoxifen for 3 subsequent
days. Control mice received equal volume of the oil-
ethanol vehicle. Mice were processed for immunostain-
ing after 2 weeks of injections.
Fig. 3 ECSF mice do not target myelinating Schwann cells. a Sciatic nerves of tamoxifen-injected ECSF; Ai14 mice were immunostained for
myelinating Schwann cells (MBP, green) and nuclei (DAPI, blue). Lower row are enlarged views of the boxed area. A few myelin sheaths show
TdTomato-expressing axons in the center (arrowheads). b Longitudinal view of the nerve shows TdTomato in axons. Representative images from
three experiments are shown. Around 10.5% of axons were found to be targeted. Scales bars = 50 μm in upper row of a and in b; 10 μm in lower
row of a. c Quantification of myelin sheaths with or without labelled axons shows 10.3% of axons are targeted in tamoxifen-injected mice. Three
mice; 5 sections/mouse; error bar, standard error of mean
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Immunofluorescence staining
Mice were euthanized and perfused with 15ml ice-cold
phosphate buffer saline (PBS), followed by 20ml 4% ice-
cold paraformaldehyde in PBS. Nerves and brains were
harvested; fixed in 4% ice-cold paraformaldehyde over-
night; cryoprotected with 10, 20, and 30% ice-cold sucrose
in PBS for 4 h, 4 h, and overnight, respectively; and frozen
in OCT (Sakura Inc). Ten Micrometre nerve sections and
40 μm brain sections were made for staining. Sections
were blocked with 5% normal donkey serum plus 0.3%
Triton® X-100 in PBS at room temperature for 1 h, incu-
bated with primary antibody in block at 4 °C overnight.
Antibodies and dilutions were: rabbit anti-p75NTR (Cell
Signaling Technology, 8238, 1:2000), rat anti-MBP (Biorad,
MCA409S, 1:100), goat anti-Gfap (Abcam, ab53554, 1:
1000), mouse anti-NeuN (Millipore, mab377, 1:200), goat
anti-Iba1 (Abcam, ab5076, 1:200), and mouse anti-CNPase
(Millipore, mab326, 1:200). Following incubation with
primary antibody, sections were washed three times with
PBS, incubated with Alexa fluorophore-conjugated sec-
ondary antibodies (1:500, Invitrogen) in block at room
temperature for 1 h, washed two times with PBS, incu-
bated with 300 nM DAPI (Sigma) at room temperature for
10m, washed two times with PBS, and mounted for con-
focal imaging (Perkin Elmer). TdTomato was strong en-
dogenously and did not require an anti-RFP antibody.
Counting of cells and axons
Cells were counted manually in tissue sections from
three each of tamoxifen- and vehicle-treated mice. At
least 4 sections per mouse per tissue were used, and at
least 20 cells were counted per section. For axons, MBP-
labelled myelin sheaths with or without TdTomato ex-
pression in the center were counted. At least 5 sections
per mouse were used, and at least 30 sheaths were
counted per section.
Fig. 4 ECSF mice sparsely label astrocytes and neurons but not microglia and oligodendrocytes in the brain. a-d Brains from tamoxifen- and
vehicle-injected ECSF; Ai14 mice were immunostained for astrocytes (Gfap), neurons (NeuN), microglia (Iba1) and oligodendrocytes (CNPase), and
nuclei (DAPI, blue). Lower rows are enlarged views of the boxed regions showing representative targeted (arrow) and untargeted (arrowheads)
cells in a and b, and representative untargeted cells (arrowheads) in C and D. Scales bars = 50 μm. e Cre activity is absent in the brain of vehicle-
injected mice. Scales bar = 50 μm. f Quantification of cells in A-D shows that 6.8% of Gfap-positive, 11.1% of NeuN-positive, 0% of Iba1-positive
and 0% of CNPase-positive cells are targeted in the cortex of tamoxifen-receiving mice. Three mice; 4 sections/mouse; error bars, standard errors
of mean
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